Pubertal development and final height after autologous bone marrow transplantation for acute lymphoblastic leukemia

Frisk, Per; Arvidson, Johan; Gustafsson, Jan Åke; Lönnerholm, Gudmar

doi:10.1038/sj.bmt.1704324

Cited by 44 publications

(71 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Puberty was induced in two girls using increasing doses of ethinylestradiol at the ages of 11.3 and 12.4 years, respectively. One girl was given a low dose of ethinylestradiol from 10.6 years of age until menarche was achieved at the age of 12.8 years.…”

Section: Methodsmentioning

confidence: 99%

Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D

Frisk

Arvidson

Ljunggren

et al. 2011

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

We measured bone mineral density (BMD) with dualenergy X-ray absorptiometry in the total body, at the lumbar spine, at the femoral neck and in the total hip, in 18 young adults with a median of 18.2 years after SCT. Fifteen patients had undergone auto-SCT and all patients had received TBI. The patients had significantly lower BMD in the total body, at the femoral neck, and in the total hip compared with age-and sex-matched controls. Six of 18 patients (33%) had low bone mass (z-score oÀ1) at one or more measurement sites, as opposed to two of the controls (11%, P ¼ 0.29). We found no significant influence of growth hormone levels or of untreated hypogonadism on BMD variables. Levels of 25-hydroxy (25(OH)) vitamin D were lower among the patients (35.2 vs 48.8 nmol/L, P ¼ 0.044) and were significantly correlated with total body BMD in the patient group (r ¼ 0.55, P ¼ 0.021). All six patients with low bone mass had hypovitaminosis D (p37 nmol/L as opposed to 4 of the 11 (36%) patients without low bone mass (P ¼ 0.035). In conclusion, we found decreased BMD in SCT survivors, which may in part be caused by 25(OH) vitamin D deficiency.

show abstract

Section: Methodsmentioning

confidence: 99%

Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D

Frisk

Arvidson

Ljunggren

et al. 2011

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

“…We found that early HSCT significantly improved the height of patients in our population, in contrast to other non-MPS IH populations after HSCT. 22,23,34 Our patients were all young (0.5-3.7 years) at the time of HSCT, even so, we still found a greater impact on height for those who were transplanted at an older age, regardless of the age at last height evaluation. This effect is consistent with other studies of children with MPS IH, which also suggested improved outcomes for those children who were transplanted at a younger age.…”

Section: Discussionmentioning

confidence: 69%

“…TBI has also frequently been associated with a considerable impact on growth compared to non-TBI conditioning regimens. 23,27,38,39 We found that 86% of children who had TBI as part of their conditioning regimen had short stature.…”

Section: Discussionmentioning

confidence: 92%

“…Early diagnosis and replacement of hormonal deficiencies are critical for optimizing growth and development. While many studies have examined long-term growth for other conditions following HSCT, [22][23][24][25][26][27][28] there are few growth data specific to patients with MPS IH. 17,19 Even less is known about endocrine function in patients with MPS IH after HSCT.…”

Section: Introductionmentioning

confidence: 99%

“…[16][17][18][19][20] HSCT as an intervention, however, compounds the problem of short stature. HSCT has been associated with growth suppression, growth hormone (GH) deficiency, abnormal gonadal and thyroid function, and damage to the epiphyseal growth plate and pituitary gland, [21][22][23][24][25][26][27][28][29] all potential causes of short stature.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation

Polgreen

Tolar

Plog

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Short stature is characteristic of Hurler syndrome, or mucopolysaccharidosis type IH (MPS IH). Hematopoietic stem cell transplantation (HSCT) is used to treat children with MPS IH. While HSCT corrects some of the metabolic features of MPS IH, its effects on growth are not well delineated. We investigated growth in patients with MPS IH after HSCT and described accompanying endocrine abnormalities. A cohort of 48 patients with MPS IH who had received HSCT between 1983 and 2005 were included. The prevalence of short stature (height oÀ2 s.d. score, SDS) before HSCT was 9%, and increased to 71% at last follow-up (6.9±5.1 years after HSCT). Short stature was positively associated with increased age at HSCT (P ¼ 0.002) and TBI (P ¼ 0.009). In total, 23% had growth hormone deficiency and/or low insulin-like growth factor-1, one female patient had premature adrenarche, one precocious puberty and 27% had clinical or subclinical hypothyroidism. Growth failure is highly prevalent in children with MPS IH after HSCT. Children who had no TBI exposure and were younger at the time of HSCT had a better height outcome.

show abstract

Consequences of Radiotherapy, Chemotherapy, and Bone Marrow Transplant

Davies¹

2005

Clinical Pediatric Endocrinology

View full text Add to dashboard Cite

Pubertal development and final height after autologous bone marrow transplantation for acute lymphoblastic leukemia

Cited by 44 publications

References 22 publications

Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D

Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D

Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation

Consequences of Radiotherapy, Chemotherapy, and Bone Marrow Transplant

Contact Info

Product

Resources

About